NCT00561327

Brief Summary

The purpose of this study is to determine whether losartan metabolites are effective in inducing PPARγ target genes in monocytes in losartan-treated patients.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2007

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

November 16, 2007

Completed
4 days until next milestone

First Posted

Study publicly available on registry

November 20, 2007

Completed
Last Updated

November 20, 2007

Status Verified

July 1, 2007

First QC Date

November 16, 2007

Last Update Submit

November 16, 2007

Conditions

Hypertension

Keywords

hypertensionangiotensin receptor blockersperoxisome proliferator activated receptor gamma

Study Arms (2)

A

Patients chronically treated with drug losartan

Drug: losartan

B

Patients not chronically treated with losartan

Interventions

losartanDRUG

Daily treated with losartan 100mg for at least the past 2 months (retrospective, no new drug treatment/ intervention)

A

Eligibility Criteria

Age19 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age: 19-80
  • Sex: male or female
  • Prior diagnosis of treated hypertension
  • Treatment with losartan 100mg/daily during at least the past 2 months (n=20/ case);
  • or: no prior angiotensin receptor 1-blocker treatment during the last 2 months (n=10/ control).

You may not qualify if:

  • Non-steroidal anti-inflammatory drugs (exception: Acetyl salicylic acid) for the past 21 days (due to structural homologies to glitazones, and activating effects on PPARγ)
  • Therapy with glitazones for the past 21 days.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

German Heart Institute

Berlin, State of Berlin, 13353, Germany

RECRUITING

MeSH Terms

Conditions

Hypertension

Interventions

Losartan

Condition Hierarchy (Ancestors)

Vascular DiseasesCardiovascular Diseases

Intervention Hierarchy (Ancestors)

Biphenyl CompoundsBenzene DerivativesHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsOrganic ChemicalsImidazolesAzolesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsTetrazoles

Study Officials

  • Eckart Fleck, Prof

    German Heart Institute

    PRINCIPAL INVESTIGATOR

  • Ulrich Kintscher, Prof

    Institute of Pharmacology Charite University Medicine Berlin Germany

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Eckart Fleck, Prof

CONTACT

+49-30-4593-2400fleck@dhzb.de

Philipp Stawowy, Dr

CONTACT

+49-30-4593-2473stawowy@dhzb.de

Study Design

Study Type
observational
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER

Study Record Dates

First Submitted

November 16, 2007

First Posted

November 20, 2007

Study Start

September 1, 2007

Last Updated

November 20, 2007

Record last verified: 2007-07

Locations

DE(1)